Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

138 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II study of combination chemotherapy with irinotecan and cetuximab for pretreated metastatic colorectal cancer harboring wild-type KRAS.
Shitara K, Yokota T, Takahari D, Shibata T, Ura T, Utsunomiya S, Inaba Y, Yamaura H, Sato Y, Najima M, Kawai H, Tajika M, Sawaki A, Yatabe Y, Muro K. Shitara K, et al. Among authors: utsunomiya s. Invest New Drugs. 2011 Aug;29(4):688-93. doi: 10.1007/s10637-009-9382-x. Epub 2010 Jan 14. Invest New Drugs. 2011. PMID: 20072801 Clinical Trial.
Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for pre-treated metastatic colorectal cancer harboring wild-type KRAS.
Shitara K, Yokota T, Takahari D, Shibata T, Ura T, Komatsu Y, Yuki S, Yoshida M, Takiuchi H, Utsunomiya S, Yatabe Y, Muro K. Shitara K, et al. Among authors: utsunomiya s. Jpn J Clin Oncol. 2010 Jul;40(7):699-701. doi: 10.1093/jjco/hyq026. Epub 2010 Mar 18. Jpn J Clin Oncol. 2010. PMID: 20304778 Clinical Trial.
Sensitivity to previous irinotecan treatment does not predict the efficacy of combination chemotherapy with cetuximab plus irinotecan for wild-type KRAS metastatic colorectal cancer.
Shitara K, Ura T, Matsuo K, Takahari D, Yokota T, Yuki S, Yoshida M, Utsunomiya S, Sato Y, Yamaura H, Kato M, Inaba Y, Tajika M, Kawai H, Yamazaki K, Komatsu Y, Muro K. Shitara K, et al. Among authors: utsunomiya s. Eur J Cancer. 2011 Dec;47(18):2673-80. doi: 10.1016/j.ejca.2011.05.015. Epub 2011 Jun 7. Eur J Cancer. 2011. PMID: 21652203
Randomised phase II study comparing dose-escalated weekly paclitaxel vs standard-dose weekly paclitaxel for patients with previously treated advanced gastric cancer.
Shitara K, Yuki S, Tahahari D, Nakamura M, Kondo C, Tsuda T, Kii T, Tsuji Y, Utsunomiya S, Ichikawa D, Hosokawa A, Ishiguro A, Sakai D, Hironaka S, Oze I, Matsuo K, Muro K. Shitara K, et al. Among authors: utsunomiya s. Br J Cancer. 2014 Jan 21;110(2):271-7. doi: 10.1038/bjc.2013.726. Epub 2013 Nov 26. Br J Cancer. 2014. PMID: 24281004 Free PMC article. Clinical Trial.
Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
Shitara K, Yuki S, Yoshida M, Takahari D, Utsunomiya S, Yokota T, Sato Y, Inaba Y, Tajika M, Kawai H, Yamaura H, Kato M, Yamazaki K, Komatsu Y, Muro K. Shitara K, et al. Among authors: utsunomiya s. Invest New Drugs. 2012 Apr;30(2):787-93. doi: 10.1007/s10637-010-9615-z. Epub 2010 Dec 22. Invest New Drugs. 2012. PMID: 21174225 Clinical Trial.
Tumor Location Is Associated With the Prevalence of Braf And Pik3ca Mutations in Patients with Wild-Type Ras Colorectal Cancer: A Prospective Multi-Center Cohort Study in Japan.
Taniguchi H, Uehara K, Nakayama G, Nakayama H, Aiba T, Hattori N, Kataoka M, Nakano Y, Kawase Y, Okochi O, Matsuoka H, Utsunomiya S, Sakamoto E, Mori Y, Umeda S, Shikano T, Komori K, Tajika M, Kadowaki S, Muro K, Yatabe Y. Taniguchi H, et al. Among authors: utsunomiya s. Transl Oncol. 2020 Jul;13(7):100786. doi: 10.1016/j.tranon.2020.100786. Epub 2020 May 16. Transl Oncol. 2020. PMID: 32428838 Free PMC article.
Hypofractionated stereotactic body radiotherapy for primary and metastatic liver tumors using the novalis image-guided system: preliminary results regarding efficacy and toxicity.
Iwata H, Shibamoto Y, Hashizume C, Mori Y, Kobayashi T, Hayashi N, Kosaki K, Ishikawa T, Kuzuya T, Utsunomiya S. Iwata H, et al. Among authors: utsunomiya s. Technol Cancer Res Treat. 2010 Dec;9(6):619-27. doi: 10.1177/153303461000900610. Technol Cancer Res Treat. 2010. PMID: 21070084 Free article. Clinical Trial.
138 results